VCP and triple-negative breast carcinoma: From a clinical perspective, the authors associated nuclear pSer784-VCP levels with poor outcomes for patients with triple-negative breast cancer receiving chemotherapy but not with other types of therapy, suggesting that pSer784-VCP might be a potential predictive biomarker for the efficacy of chemotherapy [79].